Vir Biotech stock upgraded at Morgan Stanley (VIR:NASDAQ)

Last updated: January 9, 2025 4:50 pm

By MT HANNACH

Add a Comment

0 Min Read

Disclosure: This website may contain affiliate links, which means I may earn a commission if you click on the link and make a purchase. I only recommend products or services that I personally use and believe will add value to my readers. Your support is appreciated!

Morgan Stanley upgraded Vir biotechnology (NASDAQ:VIR) at Equal Weight on Thursday after the cancer drug developer shared initial data from an interim trial for two anti-tumor agents developed using Sanofi (SNY) PRO-XTEN masking platform.

Citing the first results of two phases